The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease brings together Danish and ӳý scientists. Managing director Kasper Lage shares the center’s origin story, its achievements so far, and what the future holds.
Scientists have engineered an adeno-associated virus (AAV) that efficiently crosses the blood-brain barrier in human cell models and delivers genes throughout the brain in humanized mice.
Tightly synchronized genetic changes in two types of brain cells may underlie cognitive impairment in both conditions, offering potential therapeutic clues.
Ralda Nehme, director of ӳý’s stem cell program, talks about how stem cells can be a model for disease in a dish and what scientists can learn from these experiments.
A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.
Scientists from the US and West Africa have teamed up to build a better public health network that can quickly detect and respond to emerging viral threats.
In a pilot study with patient samples, the technology performed as well as the current gold-standard methods, yielding accurate results within hours instead of days.
Myocarditis is driven by a different immune response than the anti-tumor one, suggesting that the serious complication could one day be managed without halting cancer therapy.
Bill Sellers, head of ӳý’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.
Researchers at ӳý and MIT report the first injectable “priming agents” for liquid biopsy, which increased circulating tumor DNA by more than 10-fold in mice.